Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Last trade$1.86
Day change-$0.015 (-0.80%)
Day range$1.83 – $2.06
Volume1,336,203
Market cap$289M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$288.62M
Price / earnings
—
Price / book
3.41×
Price / sales
5.79×
EV / sales
5.06×
EV / EBITDA
-3.11×
Profitability
Earnings per share
-$0.47
Return on assets
-32.92%
Return on equity
-85.45%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.67×
Current ratio
2.82×
Quick ratio
2.82×
Cash ratio
1.3×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$110.46M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EDIT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$10.37M
$11.89M
$2.83M
$24.74M
$7.54M
$3.58M
$4.66M
$30.6M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$10.37M
$11.89M
$2.83M
$24.74M
$7.54M
$3.58M
$4.66M
$30.6M
Selling, general and administrative
$13.48M
$11.6M
$10.23M
$11.35M
$12.32M
$12.86M
$13.38M
$16.35M
Research and development
$21.17M
$20.18M
$17.6M
$27.4M
$19.78M
$16.18M
$26.59M
$48.61M
Total operating expenses
$34.65M
$30.44M
$27.83M
$32.5M
$32.09M
$55.12M
$80.82M
$77.2M
Operating income
-$24.28M
-$18.55M
-$25M
-$7.76M
-$24.55M
-$51.54M
-$76.16M
-$46.59M
Interest expense
-$1.08M
-$1.06M
-$1.07M
$464K
-$2.4M
-$2.02M
-$2.22M
-$2.19M
Income before taxes
-$23.39M
-$18.23M
-$24.98M
-$5.62M
-$25.12M
-$53.24M
-$76.09M
-$45.4M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$23.39M
-$18.23M
-$24.98M
-$5.62M
-$25.12M
-$53.24M
-$76.09M
-$45.4M
Net income attributable to common shareholders
-$23.39M
-$18.23M
-$24.98M
-$5.62M
-$25.12M
-$53.24M
-$76.09M
-$45.4M
EBITDA
-$23.9M
-$19.48M
-$24.52M
-$13.21M
-$23.83M
-$23.63M
-$33.39M
-$32.98M
Basic earnings per share
-$0.15
-$0.15
-$0.26
-$0.06
-$0.28
-$0.63
-$0.92
-$0.55
Diluted earnings per share
-$0.15
-$0.15
-$0.26
-$0.06
-$0.28
-$0.63
-$0.92
-$0.55
Recent news
Company coverage with links to the original publishers.
Editas Medicine reported a quarterly loss of $0.15 per share, beating consensus estimates of $0.21 loss, with revenues of $10.37 million significantly exceeding expectations. The stock has gained 25.4% year-to-date, outperforming the S&P 500. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Peer company Alvotech is expected to report results on November 11.
The article compares Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) as investment options for 2027. BMY trades at a cheaper valuation (9.8x forward P/E) with a 4.06% dividend yield but faces revenue concentration risks and uncertain recovery timeline. VRTX commands a higher valuation (29.8x forward P/E) but demonstrates superior growth prospects, strong margins (85.61%), and successful product launches like Alyftrek. The author recommends Vertex as the better choice, citing its strong execution and growth momentum despite higher valuation multiples.
Editas Medicine announced approval to initiate the Strive phase I/II clinical study of EDIT-401, an investigational in vivo gene-editing therapy for heterozygous familial hypercholesterolemia (HeFH) in Australia. The single-dose therapy demonstrated approximately 90% or greater reductions in atherogenic lipoproteins in preclinical primate studies. Patient dosing is planned for 2026 with initial safety data expected in Q1 2027.
Editas Medicine announced the appointment of Dan Ory, M.D., as Chief Medical Officer effective September 8, 2026. Dr. Ory brings over 25 years of experience in cardiovascular and genetic medicine, previously serving as CMO at Arbor Biotechnologies and Casma Therapeutics. He will oversee clinical development strategy as Editas advances EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia treatment, toward clinical trials.
Lyora Therapeutics, a new biotech company focused on genetic medicines for inherited retinal diseases, launched with $2.5 million in seed funding. The company's lead programs include LYA-101 for retinitis pigmentosa and LYA-102 for Usher Syndrome Type 2, with plans to submit an IND for LYA-101 within 18 months. The company is led by experienced executives from major genetic medicine firms and co-founded by renowned ophthalmology researchers.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.